JPMorgan Chase & Co. Grows Holdings in Enfusion, Inc. (NYSE:ENFN)

JPMorgan Chase & Co. grew its holdings in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 612.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 208,022 shares of the company's stock after purchasing an additional 178,821 shares during the quarter. JPMorgan Chase & Co. owned about 0.16% of Enfusion worth $1,974,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ENFN. Geode Capital Management LLC lifted its holdings in Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock worth $9,770,000 after purchasing an additional 70,367 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock worth $9,265,000 after buying an additional 61,032 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Enfusion by 167.6% in the second quarter. Renaissance Technologies LLC now owns 97,100 shares of the company's stock valued at $827,000 after acquiring an additional 60,811 shares during the period. Barclays PLC grew its stake in Enfusion by 251.4% during the third quarter. Barclays PLC now owns 86,039 shares of the company's stock valued at $817,000 after acquiring an additional 61,554 shares in the last quarter. Finally, PDT Partners LLC bought a new stake in Enfusion during the 3rd quarter worth approximately $867,000. Hedge funds and other institutional investors own 81.05% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. William Blair restated a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research note on Monday, December 23rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $10.25.

Enfusion Stock Down 0.0 %

NYSE:ENFN traded down $0.01 during midday trading on Thursday, hitting $11.11. The company had a trading volume of 511,326 shares, compared to its average volume of 1,423,727. The company has a market capitalization of $1.43 billion, a PE ratio of 277.69, a P/E/G ratio of 1.81 and a beta of 0.95. Enfusion, Inc. has a 52-week low of $7.52 and a 52-week high of $11.38. The stock's fifty day moving average price is $10.38 and its 200-day moving average price is $9.33.

Insider Transactions at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. This represents a 1.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Oleg Movchan sold 2,771 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the transaction, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. The trade was a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 57,367 shares of company stock worth $591,335. 36.44% of the stock is currently owned by corporate insiders.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.